Tech, Generics Cos. Spar With Tribes Over Allergan At PTAB

Law360, New York (December 4, 2017, 9:14 PM EST) -- Allergan’s plan to defeat inter partes reviews of patents on its eye drug Restasis by transferring them to a Native American tribe prompted over a dozen dueling amicus briefs Friday, with tech giants and generics makers decrying the deal as a “sham” and other tribes stoutly defending it.

The Patent Trial and Appeal Board last month requested amicus filings on the question of whether it lacks jurisdiction to review the Restasis patents due to the sovereign immunity possessed by the Saint Regis Mohawk Tribe, which acquired...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.